Company news

Ovid Therapeutics Inc. news in 2019

Ovid Therapeutics Inc.'s news releases, calls and decks from 2019, newest first.

View company

Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

November 17, 2019

Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

November 7, 2019

Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

October 31, 2019

Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

October 3, 2019

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

October 2, 2019

Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

September 22, 2019

Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

September 11, 2019

Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting

April 17, 2019

Decks in 2019